Go Pro
→ Where to Put $100 Before Trump's New Tech Law Rolls Out (From Brownstone Research) (Ad)tc pixel
NASDAQ:IMNN

Imunon Q2 2026 Earnings Report

Imunon logo
$1.59 -0.01 (-0.63%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$1.54 -0.05 (-2.83%)
As of 07/31/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Imunon EPS Results

Actual EPS
N/A
Consensus EPS
-$0.87
Beat/Miss
N/A
One Year Ago EPS
N/A

Imunon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Imunon Announcement Details

Quarter
Q2 2026
Date
8/4/2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 4, 2026
Conference Call Time
11:00AM ET

Conference Call Resources

Imunon Earnings Headlines

Imunon Reports Enrollment Above Expectations in Phase 3 Trial of IMNN-001 to Treat Ovarian Cancer
July 30 at 2:08 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/imunon-reports-enrollment-above-expectations-141136999.html
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
July 30 at 9:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3336139/0/en/imunon-reports-strong-enrollment-momentum-in-phase-3-ovation-3-trial-of-imnn-001-in-advanced-ovarian-cancer.html
Apple just sent a powerful signal to investors
Apple just crossed a $5 trillion market value as shares climbed 25% this year, fueled by new product launches and rising interest in foldable phones. Mode Mobile is building on top of that ecosystem with its EarnOS platform, already serving 490M+ users across 170+ countries and generating $115M+ in lifetime revenue. Deloitte ranked Mode North America's number 1 fastest-growing software company in 2023 after 32,481% growth. Pre-IPO shares are available at $0.52 before the price changes on August 14.tc pixel
August 2 at 1:00 AM  |  Mode Mobile (Ad)
IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332234/0/en/imunon-to-present-imnn-001-data-at-inaugural-aacr-conference-on-drug-discovery-and-development.html
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330491/0/en/imunon-reports-positive-phase-2-mrd-clinical-data-for-imnn-001-demonstrating-the-successful-overcoming-of-historical-il-12-safety-barriers-in-frontline-ovarian-cancer.html
Imunon Announces $7 Million Registered Direct Offering
July 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IMNN/pressreleases/36852156/imunon-announces-7-million-registered-direct-offering/
See More Imunon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Imunon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Imunon and other key companies, straight to your email.

About Imunon

Imunon (NASDAQ:IMNN), a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

View Imunon Profile
Earnings Tools